Barr Labs (BRL) Receives Final FDA Approval for Generic Version of Razadyne(R) Tablets
More News related to BRL
- Top 15 For 2008 (No. 14): M&A Wreckage
- Teva Completes Acquisition of Barr
- Warner Chilcott and Barr Announce Settlement of Femcon(R) Fe Patent Challenge
- U.S. Federal Trade Commission Clears Teva's Acquisition of Barr
- U.S. Federal Trade Commission Clears Teva's Acquisition of Barr
More News related to FDA
- Standard & Poor's Lowers Ratings on PNC Financial (PNC)
- DA Davidson Downgrades Cascade (CAE) to Underperform
- BMO Downgrades F5 Networks (FFIV) to Market Perform
- Sterne Agee Downgrades EZCorp (EZPW) to Neutral
- CL King Downgrades Steven Madden (SHOO) to Neutral
Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that its subsidiary, Barr Laboratories, Inc., received final approval from the U.S. FDA to manufacture and market a generic version of Ortho McNeil Janssen's Razadyne(R), 4 mg, 8 mg and 12 mg tablets. Barr intends to launch its generic Razadyne tablets product immediately.
Barr Pharmaceuticals, Inc. engages in the development, manufacture, and marketing of generic and proprietary pharmaceuticals.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
